Moolec Science (MLEC) Change in Acquisitions & Divestments (2023 - 2024)
Moolec Science (MLEC) reported Change in Acquisitions & Divestments of -$432386.0 for Q1 2024, down 4975.8% sequentially from $8868.0 in Q4 2023.
Moolec Science (MLEC) Change in Acquisitions & Divestments (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Change in Acquisitions & Divestments data on file, last reported at -$432386.0 in Q1 2024.
- For the quarter ending Q1 2024, Change in Acquisitions & Divestments changed N/A year-over-year to -$432386.0; the trailing twelve-month figure through Jun 2024 stood at -$144514.0 (changed N/A YoY), and the FY2024 full-year result was -$144514.0, up 94.38% from the prior year.
- Change in Acquisitions & Divestments slipped to -$432386.0 in Q1 2024, from $8868.0 in the prior quarter.
- In the past five years, Change in Acquisitions & Divestments ranged from a high of $279004.0 in Q3 2023 to a low of -$432386.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,019.86 Bn | 66,019.58 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.20 Bn | 463.41 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.50 Bn | 115.26 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.15 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 55.58 Bn | 50.39 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.43 Bn | 959.66 Mn |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -432,386.00 |
| Mar 31, 2024 | -432,386.00 |
| Dec 31, 2023 | 8,868.00 |
| Dec 31, 2023 | 8,868.00 |
| Sep 30, 2023 | 279,004.00 |
| Sep 30, 2023 | 279,004.00 |